JP2017190338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017190338A5 JP2017190338A5 JP2017141932A JP2017141932A JP2017190338A5 JP 2017190338 A5 JP2017190338 A5 JP 2017190338A5 JP 2017141932 A JP2017141932 A JP 2017141932A JP 2017141932 A JP2017141932 A JP 2017141932A JP 2017190338 A5 JP2017190338 A5 JP 2017190338A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- composition
- substituted
- kit
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000003112 inhibitor Substances 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 125000002015 acyclic group Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- -1 heteroaliphatic Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 239000003207 proteasome inhibitor Substances 0.000 claims 5
- 125000006239 protecting group Chemical group 0.000 claims 5
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims 4
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000005368 heteroarylthio group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 230000004572 zinc-binding Effects 0.000 claims 2
- LHTLDFWBUPYUDR-DUXPYHPUSA-N (2e)-3-(2,4-dichlorophenyl)-n-hydroxyacrylamide Chemical compound ONC(=O)\C=C\C1=CC=C(Cl)C=C1Cl LHTLDFWBUPYUDR-DUXPYHPUSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical group C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 claims 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960001751 fluoxymesterone Drugs 0.000 claims 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229960003690 goserelin acetate Drugs 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 229950002736 marizomib Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- TUDMPUMHSNEXAA-UHFFFAOYSA-N COCC(C1)OC(c(cc2)ccc2NC(CCCCCCC(NO)=O)=O)OC1c1ccccc1 Chemical compound COCC(C1)OC(c(cc2)ccc2NC(CCCCCCC(NO)=O)=O)OC1c1ccccc1 TUDMPUMHSNEXAA-UHFFFAOYSA-N 0.000 description 1
- REUGDYNZHDZZIH-UHFFFAOYSA-N OCCSCC(C1)OC(c(cc2)ccc2NC(CCCCCCC(NO)=O)=O)OC1c1ccccc1 Chemical compound OCCSCC(C1)OC(c(cc2)ccc2NC(CCCCCCC(NO)=O)=O)OC1c1ccccc1 REUGDYNZHDZZIH-UHFFFAOYSA-N 0.000 description 1
- SBJYFIPULXMNTC-UHFFFAOYSA-N ONC(CCCCCCC(Nc1ccc(C(OC(CSc2ccccn2)C2)OC2c2ccccc2)cc1)=O)=O Chemical compound ONC(CCCCCCC(Nc1ccc(C(OC(CSc2ccccn2)C2)OC2c2ccccc2)cc1)=O)=O SBJYFIPULXMNTC-UHFFFAOYSA-N 0.000 description 1
- YHZHZWCKPHXEEJ-UHFFFAOYSA-N ONC(CCCCCCC(Nc1ccc(C(OC(CSc2ccncc2)C2)OC2c2ccccc2)cc1)=O)=O Chemical compound ONC(CCCCCCC(Nc1ccc(C(OC(CSc2ccncc2)C2)OC2c2ccccc2)cc1)=O)=O YHZHZWCKPHXEEJ-UHFFFAOYSA-N 0.000 description 1
- KKTAUKYIHGLBHO-UHFFFAOYSA-N ONC(CCCCCCC(Nc1ccc(C(OC(CSc2nc(-c3ccccc3)c(-c3ccccc3)[o]2)C2)OC2c2ccccc2)cc1)=O)=O Chemical compound ONC(CCCCCCC(Nc1ccc(C(OC(CSc2nc(-c3ccccc3)c(-c3ccccc3)[o]2)C2)OC2c2ccccc2)cc1)=O)=O KKTAUKYIHGLBHO-UHFFFAOYSA-N 0.000 description 1
- ALLSZRCEHXENHK-UHFFFAOYSA-N ONC(CCCCCCC(Nc1ccc(C(OC(CSc2nc(cccc3)c3[s]2)C2)OC2c2ccccc2)cc1)=O)=O Chemical compound ONC(CCCCCCC(Nc1ccc(C(OC(CSc2nc(cccc3)c3[s]2)C2)OC2c2ccccc2)cc1)=O)=O ALLSZRCEHXENHK-UHFFFAOYSA-N 0.000 description 1
- XDHCWRUUURVEJL-UHFFFAOYSA-N [O-][N+](c1ccc(C2OC(c(cc3)ccc3NC(CCCCCCC(NO)=O)=O)OC(CSc3nc(-c4ccccc4)c(-c4ccccc4)[o]3)C2)cc1)=O Chemical compound [O-][N+](c1ccc(C2OC(c(cc3)ccc3NC(CCCCCCC(NO)=O)=O)OC(CSc3nc(-c4ccccc4)c(-c4ccccc4)[o]3)C2)cc1)=O XDHCWRUUURVEJL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66447005P | 2005-03-22 | 2005-03-22 | |
| US60/664,470 | 2005-03-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014180860A Division JP2014224158A (ja) | 2005-03-22 | 2014-09-05 | タンパク質分解障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017190338A JP2017190338A (ja) | 2017-10-19 |
| JP2017190338A5 true JP2017190338A5 (enExample) | 2017-11-30 |
Family
ID=37024659
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503207A Expired - Lifetime JP5744376B2 (ja) | 2005-03-22 | 2006-03-22 | タンパク質分解障害の治療 |
| JP2012266681A Withdrawn JP2013053157A (ja) | 2005-03-22 | 2012-12-05 | タンパク質分解障害の治療 |
| JP2014180860A Withdrawn JP2014224158A (ja) | 2005-03-22 | 2014-09-05 | タンパク質分解障害の治療 |
| JP2017141932A Pending JP2017190338A (ja) | 2005-03-22 | 2017-07-21 | タンパク質分解障害の治療 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503207A Expired - Lifetime JP5744376B2 (ja) | 2005-03-22 | 2006-03-22 | タンパク質分解障害の治療 |
| JP2012266681A Withdrawn JP2013053157A (ja) | 2005-03-22 | 2012-12-05 | タンパク質分解障害の治療 |
| JP2014180860A Withdrawn JP2014224158A (ja) | 2005-03-22 | 2014-09-05 | タンパク質分解障害の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8999289B2 (enExample) |
| EP (3) | EP1861126A4 (enExample) |
| JP (4) | JP5744376B2 (enExample) |
| CN (1) | CN101495116A (enExample) |
| AU (1) | AU2006226861B2 (enExample) |
| CA (2) | CA2601706C (enExample) |
| SG (1) | SG171690A1 (enExample) |
| WO (1) | WO2006102557A2 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| MX2007013494A (es) * | 2005-04-29 | 2008-01-24 | Kosan Biosciences Inc | Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag. |
| KR20080007642A (ko) * | 2005-04-29 | 2008-01-22 | 코산 바이오사이언시즈, 인코포레이티드 | 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법 |
| RU2420279C3 (ru) | 2005-08-03 | 2017-03-14 | Новартис Аг | Применение ингибиторов hdac для лечения миеломы |
| CA2627129A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
| US8222423B2 (en) | 2006-02-14 | 2012-07-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| WO2007095584A2 (en) | 2006-02-14 | 2007-08-23 | The President And Fellows Of Harvard College | Histone Deacetylase Inhibitors |
| US8304451B2 (en) * | 2006-05-03 | 2012-11-06 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| WO2008054767A2 (en) * | 2006-10-30 | 2008-05-08 | University Of Southern California | N4 modifications of pyrimidine analogs and uses thereof |
| CN101528037A (zh) * | 2006-11-03 | 2009-09-09 | 默克公司 | 使用saha和硼替佐米治疗多发性骨髓瘤的方法 |
| WO2009023846A2 (en) * | 2007-08-15 | 2009-02-19 | The Research Foundation Of State University Of New York | Methods for heat shock protein dependent cancer treatment |
| US20110118274A1 (en) * | 2007-08-23 | 2011-05-19 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
| WO2009152462A2 (en) * | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The University Of Illinois | Method of regulating cell growth using a proteasome inhibitor |
| AU2009274549B2 (en) * | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
| US20120142634A1 (en) * | 2008-11-10 | 2012-06-07 | Mount Sinai School Of Medicine Of New York University | Method of Treating Cancer with a Combination of a Proteasome Inhibitor and Salubrinal |
| CA2767697C (en) * | 2009-07-06 | 2014-10-14 | Memorial Sloan-Kettering Cancer Center | Hdac 6 inhibitor-based methods for treating cancer |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| US9597346B2 (en) * | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
| PH12012501492B1 (en) | 2010-01-22 | 2020-01-24 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| JP5469779B2 (ja) * | 2010-04-19 | 2014-04-16 | エスアールアイ インターナショナル | 多発性骨髄腫の治療のための組成物および方法 |
| WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US9476889B2 (en) * | 2011-02-24 | 2016-10-25 | Basilea Pharmaceutica Ag | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles |
| EP2508510A1 (en) | 2011-04-06 | 2012-10-10 | Ikerchem, S.L. | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| JP6374392B2 (ja) * | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| US20150320723A1 (en) * | 2013-01-07 | 2015-11-12 | St. Jude Children's Research Hospital | Use of Small Molecule Unfolder Protein Response Modulators to Treat Tumors With Active Sonic Hedgehog (SSH) Signaling Due To Smoothened (SMO) Mutation |
| PT2994465T (pt) | 2013-05-10 | 2018-10-25 | Karus Therapeutics Ltd | Novos inibidores de histona desacetilase |
| EP3021874B1 (en) * | 2013-07-18 | 2022-04-27 | The University of Hong Kong | Methods for classifying pleural fluid |
| WO2015054099A1 (en) | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| US9278963B2 (en) | 2013-10-10 | 2016-03-08 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| WO2015084905A1 (en) | 2013-12-03 | 2015-06-11 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| JP6952602B2 (ja) | 2014-07-07 | 2021-10-20 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤による白血病の治療 |
| EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
| US10365280B2 (en) | 2014-10-02 | 2019-07-30 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2972740A1 (en) * | 2015-01-14 | 2016-07-21 | Universite D'aix-Marseille | Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer |
| PL3292116T3 (pl) | 2015-02-02 | 2022-02-21 | Valo Health, Inc. | 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸 |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| EP3303306B1 (en) | 2015-06-08 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
| JP6873053B2 (ja) | 2015-06-08 | 2021-05-19 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | タンパク質脱アセチル化阻害剤の製造方法 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| GB201609786D0 (en) * | 2016-06-03 | 2016-07-20 | Karus Therapeutics Ltd | Compounds and method of use |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| ES2929032T3 (es) | 2016-08-08 | 2022-11-24 | Acetylon Pharmaceuticals Inc | Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| CN108239656A (zh) * | 2016-12-27 | 2018-07-03 | 天津天锐生物科技有限公司 | 一种小分子药物控制的蛋白功能开关系统 |
| ES2923022T3 (es) * | 2017-01-31 | 2022-09-22 | Univ Leland Stanford Junior | Agentes que inhiben Ngly1 y métodos de uso de los mismos |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| US12419832B2 (en) | 2018-01-29 | 2025-09-23 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| WO2021060567A1 (en) | 2019-09-27 | 2021-04-01 | Takeda Pharmaceutical Company Limited | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors |
| AU2020412324A1 (en) | 2019-12-26 | 2022-07-07 | Centre D'etude Des Cellules Souches (Cecs) | Combination of a proteasome inhibitor and a HDAC inhibitor and its use for the treatment of genetic diseases linked to a protein conformational disorder |
| EP4314244B1 (en) | 2021-03-23 | 2025-07-23 | Terumo BCT, Inc. | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| PL247748B1 (pl) * | 2022-03-18 | 2025-08-25 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| EP4410284A1 (en) | 2023-02-02 | 2024-08-07 | Apteeus | Compound and method for the treatment of zellweger spectrum disorder |
| CN120842303A (zh) * | 2025-07-07 | 2025-10-28 | 江南大学 | 具有urat1抑制活性的二肽及其在高尿酸血症药物中的应用 |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US523781A (en) * | 1894-07-31 | Ice-cream freezer | ||
| HU165117B (enExample) | 1971-08-12 | 1974-06-28 | ||
| US4160866A (en) * | 1976-04-30 | 1979-07-10 | Imperial Chemical Industries Limited | Carbamates |
| DE3242252A1 (de) * | 1982-11-15 | 1984-05-17 | Bayer Ag, 5090 Leverkusen | Heterocyclisch substituierte hydroxyalkyl-azolyl-derivate |
| NL194579C (nl) | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4608390A (en) * | 1985-04-26 | 1986-08-26 | Abbott Laboratories | Lipoxygenase inhibiting compounds |
| US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
| CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
| US4861798A (en) * | 1986-12-29 | 1989-08-29 | Bristol-Myers Company | Lipoxygenase inhibitory compounds |
| US4820828A (en) * | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| ES2008962A6 (es) | 1987-12-17 | 1989-08-16 | Marga Investigacion | Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol |
| EP0323590A3 (en) | 1987-12-24 | 1990-05-02 | Ono Pharmaceutical Co., Ltd. | Carbazoyl derivatives |
| JPH01224381A (ja) | 1988-03-04 | 1989-09-07 | Japan Tobacco Inc | トリコスタチン酸、トリコスタチンａの新規な合成中間体、及びトリコスタチン酸、トリコスタチンａの製造方法。 |
| EP0347381B1 (de) * | 1988-06-13 | 1992-02-12 | Ciba-Geigy Ag | Ungesättigte beta-Ketoesteracetale und ihre Anwendungen |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| WO1991000257A1 (en) | 1989-06-30 | 1991-01-10 | The Trustees Of Columbia University In The City Of New York | Novel potent inducers of terminal differentiation and methods of use thereof |
| US5176996A (en) * | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| WO1991007087A1 (en) | 1989-11-13 | 1991-05-30 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| FR2659648B1 (fr) | 1990-03-13 | 1993-02-12 | Michelin Rech Tech | Procede pour preparer un produit aromatique alkyle avec une zeolithe d'alkylation et une zeolithe de dealkylation. |
| JPH0422948A (ja) | 1990-05-18 | 1992-01-27 | Fuji Photo Film Co Ltd | 写真用処理組成物及び処理方法 |
| EP0720049B1 (en) | 1990-05-09 | 1999-08-04 | Fuji Photo Film Co., Ltd. | Photographic processing composition and processing method using the same |
| US5045538A (en) * | 1990-06-28 | 1991-09-03 | The Research Foundation Of State University Of New York | Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines |
| GB9026114D0 (en) * | 1990-11-30 | 1991-01-16 | Norsk Hydro As | New compounds |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| DE69132531T2 (de) | 1990-12-06 | 2001-09-13 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verbindungen und ihre Verwendung in einer binären Synthesestrategie |
| EP0501919A1 (de) * | 1991-03-01 | 1992-09-02 | Ciba-Geigy Ag | Strahlungsempfindliche Zusammensetzungen auf der Basis von Polyphenolen und Acetalen |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| US5225173A (en) * | 1991-06-12 | 1993-07-06 | Idaho Research Foundation, Inc. | Methods and devices for the separation of radioactive rare earth metal isotopes from their alkaline earth metal precursors |
| AU2677592A (en) | 1991-09-13 | 1993-04-27 | New England Deaconess Hospital | Erythropoietin potentiating agents and methods for their use |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5239113A (en) | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| EP0570594B1 (en) * | 1991-12-10 | 1997-07-30 | Shionogi & Co., Ltd. | Hydroxamic acid derivative based on aromatic sulfonamide |
| US5359115A (en) * | 1992-03-26 | 1994-10-25 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| WO1993019778A1 (en) | 1992-04-07 | 1993-10-14 | The Scripps Research Institute | Method for inducing tolerance to an antigen using butyrate |
| JP3356304B2 (ja) | 1992-06-16 | 2002-12-16 | 財団法人生産開発科学研究所 | 抗炎、抗潰瘍剤 |
| US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| KR100310939B1 (ko) | 1992-10-01 | 2002-06-20 | 추후제출 | 태그로암호화한복합조합화학라이브러리 |
| WO1994010300A1 (en) | 1992-10-30 | 1994-05-11 | The General Hospital Corporation | Interaction trap system for isolating novel proteins |
| US5480971A (en) * | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| US5440016A (en) * | 1993-06-18 | 1995-08-08 | Torrey Pines Institute For Molecular Studies | Peptides of the formula (KFmoc) ZZZ and their uses |
| US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US20030203976A1 (en) * | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
| US5362899A (en) | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
| US5659016A (en) | 1994-09-22 | 1997-08-19 | Cancer Institute | RPDL protein and DNA encoding the same |
| US6231600B1 (en) * | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
| US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| JP3330781B2 (ja) | 1995-05-22 | 2002-09-30 | 三菱エンジニアリングプラスチックス株式会社 | ポリカーボネート樹脂組成物 |
| WO1997011366A1 (en) | 1995-09-20 | 1997-03-27 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
| EP0774464B1 (en) | 1995-10-17 | 2004-07-28 | Combichem, Inc. | A template for solution phase synthesis of combinatorial libraries |
| JPH09124918A (ja) | 1995-10-30 | 1997-05-13 | Mitsubishi Eng Plast Kk | ポリカーボネート樹脂組成物 |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6068987A (en) * | 1996-09-20 | 2000-05-30 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| NZ500590A (en) | 1997-04-22 | 2001-11-30 | Cocensys Inc | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| US6190619B1 (en) | 1997-06-11 | 2001-02-20 | Argonaut Technologies, Inc. | Systems and methods for parallel synthesis of compounds |
| US5891507A (en) * | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
| US6195612B1 (en) * | 1998-01-05 | 2001-02-27 | Tama L. Pack-Harris | Pharmacy benefit management system and method of using same |
| US6503708B1 (en) * | 1998-01-26 | 2003-01-07 | Incyte Genomics, Inc. | Microtubule-associated protein |
| US6428960B1 (en) * | 1998-03-04 | 2002-08-06 | Onyx Pharmaceuticals, Inc. | Selection method for producing recombinant baculovirus |
| US6037361A (en) * | 1998-03-09 | 2000-03-14 | Warner-Lambert Company | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6248127B1 (en) * | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| DE19846008A1 (de) | 1998-10-06 | 2000-04-13 | Bayer Ag | Phenylessigsäure-heterocyclylamide |
| TR200101663T2 (tr) | 1998-12-10 | 2001-11-21 | F.Hoffmann-La Roche Ag | Pro-kollajen c-proteinaz inhibitörleri |
| AU3118200A (en) | 1998-12-14 | 2000-07-03 | Merck & Co., Inc. | Hiv integrase inhibitors |
| CA2355075C (en) | 1998-12-16 | 2009-12-08 | Aventis Pharma Limited | Heteroaryl-cyclic acetals |
| AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
| US6258121B1 (en) * | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
| US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
| EP1748046A3 (en) * | 1999-11-23 | 2007-08-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6251136B1 (en) * | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| US20030129724A1 (en) * | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1335898B1 (en) * | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| US7314953B2 (en) | 2001-03-27 | 2008-01-01 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| AR035455A1 (es) * | 2001-04-23 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
| US7244853B2 (en) * | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| WO2002089782A2 (en) | 2001-05-09 | 2002-11-14 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JP2003221398A (ja) | 2001-11-22 | 2003-08-05 | Japan Science & Technology Corp | 蛍光又は発色基質を用いたヒストンデアセチラーゼ活性測定法 |
| US6517889B1 (en) * | 2001-11-26 | 2003-02-11 | Swaminathan Jayaraman | Process for coating a surface of a stent |
| AU2002362030A1 (en) * | 2001-11-27 | 2003-06-10 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| CN101259120B (zh) * | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
| NO20032183L (no) | 2002-05-15 | 2003-11-17 | Schering Ag | Histon-deacetylase-inhibitor og anvendelse derav |
| JP2004043446A (ja) | 2002-05-15 | 2004-02-12 | Schering Ag | ヒストンデアセチラーゼ抑制剤及びその使用 |
| WO2003101481A1 (en) * | 2002-06-03 | 2003-12-11 | Als Therapy Development Foundation | Treatment of neurodegenerative diseases using proteasome modulators |
| TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| US6726705B2 (en) | 2002-06-25 | 2004-04-27 | Incisive Surgical, Inc. | Mechanical method and apparatus for bilateral tissue fastening |
| TW200420573A (en) * | 2002-09-26 | 2004-10-16 | Rib X Pharmaceuticals Inc | Bifunctional heterocyclic compounds and methods of making and using same |
| AU2003273701A1 (en) * | 2002-10-17 | 2004-05-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP1565193B1 (en) * | 2002-11-06 | 2013-04-24 | Dana-Farber Cancer Institute, Inc. | Compositions for treating cancer using proteasome inhibitor PS-341 |
| KR101076018B1 (ko) | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
| JP4790594B2 (ja) * | 2003-02-25 | 2011-10-12 | トポターゲット ユーケー リミテッド | Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物 |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| WO2005007091A2 (en) | 2003-07-07 | 2005-01-27 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| US7842835B2 (en) * | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| WO2005012247A1 (en) | 2003-07-30 | 2005-02-10 | Hôpital Sainte-Justine | Compounds and methods for the rapid quantitative analysis of proteins and polypeptides |
| SI1663194T1 (sl) | 2003-08-26 | 2010-08-31 | Merck Hdac Res Llc | Uporaba SAHA za zdravljenje mezotelioma |
| EP1541549A1 (en) | 2003-12-12 | 2005-06-15 | Exonhit Therapeutics S.A. | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| JP4989976B2 (ja) | 2004-02-13 | 2012-08-01 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 翻訳開始阻害剤としての３−３−二置換オキシインドール |
| WO2006006080A2 (en) | 2004-07-08 | 2006-01-19 | Bizmedic Co., Ltd. | Sodium channel agonist |
| SG157365A1 (en) * | 2004-12-03 | 2009-12-29 | Dana Farber Cancer Inst Inc | Compositions and methods for treating neoplastic diseases |
| CA2590334A1 (en) | 2004-12-03 | 2006-06-08 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| US20070062152A1 (en) * | 2005-09-12 | 2007-03-22 | Nokia Corporation | Domesheet assembly in a keyboard |
| TWM290175U (en) * | 2005-09-20 | 2006-05-01 | Chian-Hung Ju | Structure of the light building materials with sound absorption and insulation function |
| US7438916B2 (en) * | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
| WO2007095584A2 (en) * | 2006-02-14 | 2007-08-23 | The President And Fellows Of Harvard College | Histone Deacetylase Inhibitors |
| US8222423B2 (en) * | 2006-02-14 | 2012-07-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| EP2007383A4 (en) | 2006-03-22 | 2010-09-15 | Univ California | HEMMER OF PROTEIN PRENYL TRANSFERASES |
| US8304451B2 (en) * | 2006-05-03 | 2012-11-06 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| US20070282010A1 (en) * | 2006-05-30 | 2007-12-06 | Bridge Pharma, Inc. | Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CN105481788A (zh) * | 2006-10-28 | 2016-04-13 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| JP2011500783A (ja) | 2007-10-22 | 2011-01-06 | オーキッド リサーチ ラボラトリーズ リミテッド | ヒストンデアセチラーゼ阻害剤 |
| EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| US8467034B2 (en) * | 2008-07-02 | 2013-06-18 | Nikon Corporation | Light shielding unit, variable slit apparatus, and exposure apparatus |
| AU2009274549B2 (en) * | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
| WO2010019924A1 (en) * | 2008-08-15 | 2010-02-18 | Burnham Institute For Medical Research | Composition and methods for the design and development of metallo-enzyme inhibitors |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| US20130040998A1 (en) * | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
-
2006
- 2006-03-22 US US11/386,959 patent/US8999289B2/en active Active
- 2006-03-22 CA CA2601706A patent/CA2601706C/en not_active Expired - Fee Related
- 2006-03-22 EP EP06748614A patent/EP1861126A4/en not_active Withdrawn
- 2006-03-22 SG SG201103495-6A patent/SG171690A1/en unknown
- 2006-03-22 JP JP2008503207A patent/JP5744376B2/ja not_active Expired - Lifetime
- 2006-03-22 AU AU2006226861A patent/AU2006226861B2/en not_active Ceased
- 2006-03-22 EP EP12150229.8A patent/EP2491926B1/en not_active Expired - Lifetime
- 2006-03-22 EP EP18157889.9A patent/EP3354265A1/en not_active Withdrawn
- 2006-03-22 CA CA2937005A patent/CA2937005A1/en not_active Abandoned
- 2006-03-22 WO PCT/US2006/010676 patent/WO2006102557A2/en not_active Ceased
- 2006-03-22 CN CNA2006800177289A patent/CN101495116A/zh active Pending
-
2012
- 2012-12-05 JP JP2012266681A patent/JP2013053157A/ja not_active Withdrawn
-
2014
- 2014-09-05 JP JP2014180860A patent/JP2014224158A/ja not_active Withdrawn
-
2015
- 2015-04-06 US US14/679,800 patent/US9572854B2/en not_active Expired - Lifetime
-
2017
- 2017-01-09 US US15/401,902 patent/US10172905B1/en not_active Expired - Lifetime
- 2017-07-21 JP JP2017141932A patent/JP2017190338A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017190338A5 (enExample) | ||
| JP6863981B2 (ja) | グルタミン類似体のプロドラッグ | |
| JP2021520345A5 (enExample) | ||
| EA200601252A1 (ru) | Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения | |
| KR101174685B1 (ko) | Ｇｓｔ-활성화된 항암 화합물을 사용한 치료에 의한 또다른항암 치료법에 대한 민감화 및/또는 또다른 항암 치료법의부작용의 개선 | |
| IL278297B2 (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| JP2009509910A5 (enExample) | ||
| RU2003127391A (ru) | Лечение рака | |
| JP2010265305A (ja) | Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療 | |
| EP3331851A1 (en) | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof | |
| JP2016505621A5 (enExample) | ||
| JP2018514562A5 (enExample) | ||
| CN104829671B (zh) | No供体型的吉西他滨/fta/呋咱缀合物及制备方法和用途 | |
| RU2016149761A (ru) | Производные нуклеозидов для лечения ракового заболевания | |
| EP3471774A1 (en) | Porphyrin compounds and compositions useful for treating cancer | |
| ES2535452B1 (es) | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas | |
| RU2015113959A (ru) | Индолины | |
| EP3888647B1 (en) | Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as combination drug | |
| AR040520A1 (es) | Derivados de pirazol heterociclicos condensados, como inhibidores de la quinasa | |
| JP2018531995A5 (enExample) | ||
| ES2369440T3 (es) | Método para el tratamiento de la hepatitis viral de tipo c crónica usando ro 113-0830. | |
| CA2511242A1 (en) | Inhibitors of human tumor-expressed ccxckr2 | |
| WO2019157338A1 (en) | Mebendazole prodrugs with enhanced solubility and oral bioavailability | |
| ES2210774T3 (es) | Nuevas cianoaziridinas para el tratamiento del cancer. | |
| CN1917867A (zh) | 具有抗肿瘤活性的化合物 |